Enigma Diagnostics Taps Tecan to Make and Market Forthcoming POC Molecular Dx Platform | GenomeWeb

This story was originally published on Feb. 9.

By Ben Butkus

Enigma Diagnostics has taken an important step toward commercializing its PCR-based, point-of-care molecular diagnostic platform by inking a global manufacturing and supply agreement with Tecan.

Enigma, based in Oxford, UK, said that it struck the alliance with Tecan in anticipation of a fourth-quarter commercial launch of its platform for point-of-care influenza diagnostic tests in Europe in partnership with GlaxoSmithKline.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."